UCSF landed $824 million in NIH awards for fiscal 2025, funding AI, cancer and infectious‑disease research and boosting the Bay Area life‑sciences economy. The haul cements UCSF’s status as the top public NIH recipient in 2025.

The Global Virus Network cut the ribbon on its international headquarters at USF on March 5, bringing Robert Gallo and global virology programs to Tampa Bay. University and network leaders say the move strengthens local research, training and pandemic preparedness.

A San Francisco federal judge temporarily blocked Perplexity's Comet browser from shopping on Amazon and ordered collected Amazon data destroyed.

Illinois institutions took in $1.26B in NIH awards in 2025 — down 12.4% as grant counts fell and the agency shifted priorities. That pullback is squeezing Chicago's research hubs.

AbbVie's ABBV‑295 produced nearly 10% weight loss in a 76‑person Phase 1 readout, with mostly mild side effects; full data are pending conference presentation.

United Therapeutics' Phase 3 ralinepag cut clinical worsening risk by 55% and the company says the drug could be a $2B rival to J&J's Uptravi.

Federal probes into banks' AI hiring tools raise questions about bias in résumé screeners. Here’s what researchers and regulators are watching and how applicants can respond.

A St. Louis nonprofit’s white paper argues recurring drug shortages reflect structural fragility and proposes a National Fragility Index to guide purchasing and investment.

A coalition of tech researchers sued in D.C., arguing a visa policy singles out foreign experts who study social media and chills vital research.

A 1,323-pound NASA probe managed out of Maryland is expected to re-enter Earth’s atmosphere Tuesday night. Officials say the chance of debris hitting a person is extremely small.

USF’s reported research expenditures climbed to $531M — a 15% gain in two years that is drawing federal and private dollars into Tampa Bay.

A Triangle Business Journal ranking shows the region’s 25 biggest VC backers raised about $1.5B in 2025, highlighting concentrated capital and a life‑sciences tilt.

Vertex’s kidney‑disease candidate povetacicept met primary and secondary Phase 3 goals in a Week 36 interim readout, clearing an accelerated path toward an FDA filing this month.